NLS Pharmaceutics Reports Results From Study KO-874 On Mazindol's Neuroprotective Effects In Narcoleptic-Like Rat Model
NLS Pharmaceutics Reports Results From Study KO-874 On Mazindol's Neuroprotective Effects In Narcoleptic-Like Rat Model
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced promising results from its preclinical study KO-874 at the American Society of Clinical Psychopharmacology (ASCP) in Miami. This study evaluated the neuroprotective effects of mazindol on nocturnal activity in a rat model with narcoleptic-like symptoms induced by orexin-B-saporin (OX-B-SAP) lesions in the lateral hypothalamus (LH).
瑞士临床阶段生物制药公司NLS Pharmaceutics Ltd.（纳斯达克股票代码：NLSP，NLSPW）（以下简称“NLS”或“公司”）致力于开创罕见和复杂的中枢神经系统疾病的治疗方法，并在美国临床精神药理学会（ASCP）在迈阿密举行的会议上，发布了KO-874临床前研究的良好结果。该研究评估了Ma的神经保护作用在一种老鼠夜间活动模型中的效果，该模型由侧下丘脑（LH）中orexin-B-saporin（OX-B-SAP）病变诱导的阿魏酸盐类似症状引起。